908 Devices (MASS) Q3 2026: Revenue Surges 35% on Record Device Shipments

908 Devices reported third-quarter 2026 revenue of $18.95 million, up 35% year over year and ahead of the $18.31 million consensus estimate by about 3.5%. Product revenue drove most of that growth, reaching $15.76 million compared with $10.84 million in the same period a year earlier. The quarter marked the first full contribution from the NIRLab acquisition, which added both device volume and a growing stream of recurring revenue.

Device placements hit a company record of 308 units in the quarter, lifting the installed base 26% year over year to 4,409 devices. Recurring revenue came in at $5.1 million, representing 27% of total revenue. CEO Kevin J. Knopp credited the FTIR portfolio for leading the charge, noting that platforms are "winning orders across the globe as customers accelerate efforts to modernize their detection capabilities and stay ahead of an evolving threat landscape."

On the bottom line, the company posted a GAAP loss of $0.11 per share, just a penny wider than the $0.105 consensus estimate, a miss of roughly 5%. The net loss from continuing operations narrowed sharply to $4.60 million from $14.90 million a year earlier, helped in large part by an $11.0 million noncash swing in contingent consideration fair value that had been a significant charge in the prior-year quarter. Stripping out that item alongside $109 thousand from NIRLab holdback share revaluation, $62 thousand in acquisition and integration costs, and $93 thousand in restructuring charges gives a cleaner picture of underlying operating progress.

Management raised the low end of its full-year 2026 revenue guidance, now targeting $68.5 million to $70.0 million, up from the prior range of $68.0 million to $70.0 million. That updated range implies 22% to 25% growth over 2025. The rationale cited included growing FTIR demand, NIRLab pipeline traction, and healthy customer funding levels heading into year-end.

Knopp also flagged that NIRLab is gaining traction in both unit volumes and pipeline, positioning the segment as a building block for connected, recurring revenue. Gross profit rose 36% year over year to just over $10 million, suggesting the revenue mix is holding its margin profile even as the company absorbs integration costs. Total liabilities fell 9.2% year over year to $49.6 million while shareholders' equity grew nearly 10% to $149.8 million, reflecting a balance sheet that has been strengthening alongside top-line momentum.